Literature DB >> 7910974

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness.

R Ganguli1, Z Yang, G Shurin, K N Chengappa, J S Brar, A V Gubbi, B S Rabin.   

Abstract

Using an enzyme immunoassay (ELISA), we measured serum interleukin-6 (IL-6) concentration in 128 schizophrenic patients (24 of whom were never medicated) and in 110 normal control subjects. Mean serum IL-6 concentration was significantly higher in the schizophrenic patients as compared with the control subjects (p = 0.009). Comparisons within the patient group revealed that serum IL-6 was significantly correlated with duration of illness (r = 0.32, p = 0.0004). After covariation for duration of illness, there was no relationship between IL-6 levels and the production of autoantibodies, clinical state, or medication status. Thus, elevated serum IL-6 levels in schizophrenia develop during the course of illness and may be related to treatment or to disease progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910974     DOI: 10.1016/0165-1781(94)90042-6

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  40 in total

1.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

Review 2.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

3.  Prenatal maternal immune disruption and sex-dependent risk for psychoses.

Authors:  J M Goldstein; S Cherkerzian; L J Seidman; J-A L Donatelli; A G Remington; M T Tsuang; M Hornig; S L Buka
Journal:  Psychol Med       Date:  2014-03-26       Impact factor: 7.723

Review 4.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

5.  Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders.

Authors:  Demian Obregon; Ellisa Carla Parker-Athill; Jun Tan; Tanya Murphy
Journal:  Neuropsychiatry (London)       Date:  2012-08

6.  Immune System and Schizophrenia.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Curr Immunol Rev       Date:  2010-08

Review 7.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

9.  Plasma cytokine response to surgical stress in schizophrenic patients.

Authors:  A Kudoh; T Sakai; H Ishihara; A Matsuki
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

Review 10.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.